Please login to the form below
Ranbaxy
This page shows the latest Ranbaxy news and features for those working in and with pharma, biotech and healthcare.
Nearly half of all clinical trials not published
Drilling down into the data provides a mixed picture for the pharma industry - at one end of the scale is Ranbaxy, which has published no results for any of the 35
Latest news
-
Lundbeck challenge to EC pay-for-delay ruling fails
The four generics companies - Generics UK, Arrow, Alpharma and Ranbaxy - were fined around 52m, and those judgments have also been upheld by the General Court of the EU.
-
India denies Vertex patent on cystic fibrosis drug Orkambi
The patent was opposed by the Indian Pharmaceutical Alliance (IPA), a trade organisation representing India's larger pharmaceutical companies, including Cipla, Dr Reddy's Labs, Lupin, Nicholas Piramal, Ranbaxy and Wockhardt.
-
Heart drug sales continue downward spiral
The Swiss firm has managed to delay some generic forms of its drug onto the market until last year, when Ranbaxy was granted approval to sell its copycat form of valsartan.
-
Takeda to pay $2.4bn to settle Actos cancer suits
Actos has generated more than $16bn in sales since its 1999 release, according to court filings, but now also faces generic competition from India's Ranbaxy Laboratories.
-
Teva slapped with $512m fine on pay-for-delay deal
Ranbaxy Laboratories. ... Mylan and Ranbaxy, which are also defendants in the case, are not part of the settlement.
More from news
Approximately 7 fully matching, plus 107 partially matching documents found.
Latest Intelligence
-
Pharma deals in April 2015
The acquisition of this portfolio with sales of INR 150 Crores, will help Dr Reddy's maintain a competitive edge with fellow Indian rival Sun Pharmaceuticals, following its acquisition of Ranbaxy
-
Allergan and taking a specialised approach
But for the likes of GSK, Novartis and Lilly with their asset swap agreement, Forest Laboratories and its acquisition of Actavis, and the various dealings at Merck &Co, BMS, Ranbaxy and
-
Pharma deals during April 2014
The total cost of the all-stock acquisition is $4.0bn (an 18% premium), $3.2bn in stock and nearly $800m of Ranbaxy debt. ... Eclipsing all else will be restoring FDA confidence. To this end immediate remedial action will involve management restructuring
-
Deal Watch table for April 2014
Ranbaxy Laboratories/ Sun Pharmaceuticals. Acquisition. Generics including Lipitor, Nexium, Diovan. 3, 200.
-
Positive prospects for pharma in Latin America
Since 2008, more foreign companies such as Takeda, Daiichi Ranbaxy and others have been allowed to set operations in the country, increasing competition and consolidation.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
Competition from within
Teva (Israel), CSL (Australia) and Aspen (South Africa) are notable exceptions, with the Indian generic giants Sun and Ranbaxy - which have since merged - the only representation from the ‘ BRIC’ markets (Brazil,
-
Exploring MINT: Part 3 - Nigeria
At present, antiretroviral treatment is primarily funded by philanthropic organisations, with generic companies such as Indian Cipla, Hetero and Ranbaxy among those supplying low-cost generic ARVs to African governments.
-
Exploring MINT: Part 3 - Nigeria
At present, antiretroviral treatment is primarily funded by philanthropic organisations, with generic companies such as Indian Cipla, Hetero and Ranbaxy among those supplying low-cost generic ARVs to African governments.
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Featured jobs
- Senior Writer, Healthcare Advertising, London
-
Excellent package
- Account Director or Senior Account Director
-
Salary TBC
-
Senior Medical Writer
-
Salary is DOE
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
- Senior Medical Writer, Principal Medical Writer, Scientific Dire...
-
£40000 - £75000 Bonus Benefits
-
Systematic Review Lead- London
-
Negotiable
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Senior Strategist/ Planner, Healthcare Marketing, London
-
Excellent package
- Sudler London - Senior Medical Writer
-
Competitive
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
-
Associate Scientific Director
-
Salary TBC
-
Healthcare PR Senior Account Manager
-
Salary TBC
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
Subscribe to our email news alerts
- Tox trouble stalls Sosei/Allergan Alzheimer’s drug
- London cancer hub launched by Cancer Research UK
- Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma
- Making a Difference - The Future of Pharma
- AZ prepares to file COPD triple, taking on rival GSK
- Controversy grows around GP at Hand service after minister’s endorsement
PMHub
EY Life Sciences
Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
